2022 February 16, 2022 Memo Therapeutics AG Closes Series B Financing at CHF37 Million Following Oversubscribed CHF23 Million Extension January 14, 2022 Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa January 03, 2022 Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
